Molecular Characterization and Clinical Impact of TMPRSS2-ERG Rearrangement on Prostate Cancer: Comparison between FISH and RT-PCR

Molecular Characterization and Clinical Impact of TMPRSS2-ERG Rearrangement on Prostate Cancer: Comparison between FISH and RT-PCR

Prostate cancer (PCa) is a very heterogeneous disease, and there are constraints in its current diagnosis. Serum PSA levels, digital rectal examination (DRE), and histopathologic analysis often drive to overdiagnosis and overtreatment. Since 2005, the presence of the genetic rearrangement between tr...

Full description

Bibliographic Details
Main Authors:	A. Fernández-Serra, L. Rubio, A. Calatrava, J. Rubio-Briones, R. Salgado, R. Gil-Benso, B. Espinet, Z. García-Casado, J. A. López-Guerrero
Format:	Article
Language:	English
Published:	Hindawi Limited 2013-01-01
Series:	BioMed Research International
Online Access:	http://dx.doi.org/10.1155/2013/465179

Similar Items

Molecular Composition of Genomic TMPRSS2-ERG Rearrangements in Prostate Cancer
by: Manuela Krumbholz, et al.
Published: (2019-01-01)

Insulin-like growth factor 1 receptor affects the survival of primary prostate cancer patients depending on TMPRSS2-ERG status
by: Caterina Mancarella, et al.
Published: (2017-05-01)

Role of the TMPRSS2-ERG Gene Fusion in Prostate Cancer
by: Scott A. Tomlins, et al.
Published: (2008-02-01)

BRD4 Promotes DNA Repair and Mediates the Formation of TMPRSS2-ERG Gene Rearrangements in Prostate Cancer
by: Xiangyi Li, et al.
Published: (2018-01-01)

Overexpression of truncated ERG from TMPRSS2-ERG fusion and prostate cancer development
by: Melanie Leong, et al.
Published: (2009-09-01)

Impact TMPRSS2–ERG Molecular Subtype on Prostate Cancer Recurrence
by: Anastasiya A. Kobelyatskaya, et al.
Published: (2021-06-01)

5' UTR control of native ERG and of Tmprss2:ERG variants activity in prostate cancer.
by: Francesca Zammarchi, et al.
Published: (2013-01-01)

TMPRSS2: ERG expression in prostate cancer: Imaging and clinico-pathological correlations
by: V. Fasulo, et al.
Published: (2020-10-01)

Three-Color FISH Analysis of TMPRSS2/ERG Fusions in Prostate Cancer Indicates That Genomic Microdeletion of Chromosome 21 Is Associated with Rearrangement
by: Maisa Yoshimoto, et al.
Published: (2006-06-01)

PCA3 and TMPRSS2-ERG: Promising Biomarkers in Prostate Cancer Diagnosis
by: Jack A. Schalken, et al.
Published: (2010-07-01)

Dual TMPRSS2:ERG Fusion in a Patient with Lung and Prostate Cancers
by: Francesca Giunchi, et al.
Published: (2020-12-01)

Study of the mechanisms causing the TMPRSS2:ERG gene fusion in prostate cancer
by: Coll Bastus, Nuria
Published: (2013)

Noninvasive Detection of TMPRSS2:ERG Fusion Transcripts in the Urine of Men with Prostate Cancer
by: Bharathi Laxman, et al.
Published: (2006-10-01)

Diagnostic value of PCA3, TMPRSS2:ERG and prostatic specific antigen derivatives in the detection of prostate cancer
by: A. A. Musaelyan, et al.
Published: (2020-07-01)

Detection of tmprss2-erg and tmprss2-egr1 gene fusion in prostate cancer from a Chinese population
by: Changqing Xu, et al.
Published: (2020-12-01)

A TMPRSS2‐ERG gene signature predicts prognosis of patients with prostate adenocarcinoma
by: Emily Zhou, et al.
Published: (2020-12-01)

TMPRSS2-ERG expression predicts prostate cancer survival and associates with stromal biomarkers.
by: Christina Hägglöf, et al.
Published: (2014-01-01)

TMPRSS2-ERG Gene Fusion Causing ERG Overexpression Precedes Chromosome Copy Number Changes in Prostate Carcinomas, Paired HGPIN Lesions
by: Nuno Cerveira, et al.
Published: (2006-10-01)

Antineoplastic Effects of siRNA against TMPRSS2-ERG Junction Oncogene in Prostate Cancer.
by: Giorgia Urbinati, et al.
Published: (2015-01-01)

<it>TMPRSS2-ERG </it>-specific transcriptional modulation is associated with prostate cancer biomarkers and TGF-β signaling
by: Brase Jan C, et al.
Published: (2011-12-01)

Status of TMPRSS2–ERG fusion in prostate cancer patients from India: correlation with clinico-pathological details and TMPRSS2 Met160Val polymorphism
by: Aparna Bhanushali, et al.
Published: (2018-12-01)

Antibody-Based Detection of ERG Rearrangement-Positive Prostate Cancer
by: Kyung Park, et al.
Published: (2010-07-01)

Two paths for stabilization of ERG in prostate carcinogenesis: TMPRSS2-ERG fusions and speckle-type pox virus and zinc finger protein mutations
by: Laura E Pascal, et al.
Published: (2016-01-01)

Whole Transcriptome Analysis Reveals Established and Novel Associations with TMPRSS2:ERG Fusion in Prostate Cancer
by: Chow, Anthony
Published: (2012)

Whole Transcriptome Analysis Reveals Established and Novel Associations with TMPRSS2:ERG Fusion in Prostate Cancer
by: Chow, Anthony
Published: (2012)

SFRP1 increases TMPRSS2-ERG expression promoting neoplastic features in prostate cancer in vitro and in vivo
by: Carlos D. Cruz-Hernández, et al.
Published: (2020-07-01)

Deletion of 3p13 is a late event linked to progression of TMPRSS2:ERG fusion prostate cancer
by: Kluth M, et al.
Published: (2018-11-01)

Comprehensive metabolomics analysis of prostate cancer tissue in relation to tumor aggressiveness and TMPRSS2-ERG fusion status
by: Ilona Dudka, et al.
Published: (2020-05-01)

Comprehensive analysis of oncogenic signatures and consequent repurposed drugs in TMPRSS2:ERG fusion‐positive prostate cancer
by: Jae Won Yun, et al.
Published: (2021-05-01)

ERG induces epigenetic activation of Tudor domain-containing protein 1 (TDRD1) in ERG rearrangement-positive prostate cancer.
by: Lukasz A Kacprzyk, et al.
Published: (2013-01-01)

Clinical impact of combined PTEN and ERG rearrangements in localized prostate cancer
by: Charalampos Fragkoulis, et al.
Published: (2021-03-01)

ERG rearrangement is associated with prostate cancer-related death in Chinese prostate cancer patients.
by: Mei Qi, et al.
Published: (2014-01-01)

Cysteine-rich secretory protein-3 (CRISP3) is strongly up-regulated in prostate carcinomas with the TMPRSS2-ERG fusion gene.
by: Franclim R Ribeiro, et al.
Published: (2011-01-01)

Comparative Evaluation of Urinary PCA3 and TMPRSS2: ERG Scores and Serum PHI in Predicting Prostate Cancer Aggressiveness
by: Lucile Tallon, et al.
Published: (2014-07-01)

EZH2-induced lysine K362 methylation enhances TMPRSS2-ERG oncogenic activity in prostate cancer
by: Marita Zoma, et al.
Published: (2021-07-01)

Celastrol suppresses tumor cell growth through targeting an AR-ERG-NF-κB pathway in TMPRSS2/ERG fusion gene expressing prostate cancer.
by: Longjiang Shao, et al.
Published: (2013-01-01)

Role of TMPRSS2-ERG gene fusion in negative regulation of PSMA expression.
by: Lihong Yin, et al.
Published: (2011-01-01)

Association of TMPRSS2-ERG gene fusion with clinical characteristics and outcomes: results from a population-based study of prostate cancer
by: Gleave Martin E, et al.
Published: (2008-08-01)

TMPRSS2-ERG fusions confer efficacy of enzalutamide in an in vivo bone tumor growth model
by: Louie Semaan, et al.
Published: (2019-10-01)

Upregulation of the transcription factor TFAP2D is associated with aggressive tumor phenotype in prostate cancer lacking the TMPRSS2:ERG fusion
by: Christoph Fraune, et al.
Published: (2020-03-01)